


We claim:

1. A compound of the formula (I)



wherein

$R_1$  and  $R_2$  are independently H or  $\text{SO}_3\text{H}$ ,

and/or a physiologically tolerated salt thereof and/or an obvious chemical equivalent.

2. The compound according to claim 1, wherein  $R_1$  and  $R_2$  are  $\text{SO}_3\text{H}$ .

3. The compound according to claim 1, wherein  $R_1$  and  $R_2$  are H.

4. The compound according to claim 1, obtained by cultivating *Cryphonectria parasitica*, DSM 14453 or one of its variants or mutants.

5. The compound according to claim 1, of the molecular formula  $\text{C}_{35}\text{H}_{54}\text{O}_{12}\text{S}_2$  and further characterized by the  $^1\text{H}$  NMR data ( $\delta$  in ppm) 0.85, 0.88, 1.23, 1.23-1.32, 1.25, 1.31, 1.45, 1.50, 1.57, 1.59, 2.45, 2.55, 5.04, 6.12, 6.14, 6.72, 6.75, 9.75, 10.48 and by the  $^{13}\text{C}$  NMR data ( $\delta$  in ppm) 13.74, 13.87, 18.07, 22.00, 24.82, 28.60, 28.80-28.99, 29.13, 30.81, 31.20, 31.33, 33.58, 34.41, 35.23, 35.76, 74.23, 100.38, 108.63, 109.02, 110.23, 114.85, 142.54, 144.32, 153.56, 159.71, 160.21, 169.25.

6. The compound according to claim 1, of the molecular formula  $\text{C}_{35}\text{H}_{54}\text{O}_6$  and further characterized by the  $^1\text{H}$  NMR data ( $\delta$  in ppm) 0.84, 0.88, 1.25, 1.26,

1.33/1.29, 1.39/1.33, 1.45, 1.46, 1.56, 1.58, 2.34, 2.55, 5.05, 6.00, 6.12, 6.14 and by the  $^{13}\text{C}$  NMR data ( $\delta$  in ppm) 13.75, 13.87, 18.08, 22.02, 24.84, 28.91-28.62, 28.91-28.62, 29.19, 30.67, 31.22, 31.39, 33.59, 34.49, 35.25, 35.78, 74.19, 99.91, 100.39, 106.20, 108.75, 144.08, 144.43, 158.11, 159.89, 160.37, 169.31.

5

7. A process for the preparation of a compound according to claim 1, comprising: (a) cultivating *Cryphonectria parasitica*, DSM 14453 or one of its variants or mutants, (b) isolating and optionally purifying compound of the formula (I), and (c) converting where appropriate into a physiologically tolerated salts or an obvious chemical equivalent.

10

8. A method of treating a patient in need thereof, for the treatment and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, stroke, psychosis or depression; comprising administering to the patient an effective amount of a compound of the formula (I) or a physiologically tolerated salt or obvious equivalent thereof.

15

9. A pharmaceutical composition, comprising at least one compound according to claim 1, and at least one pharmaceutically acceptable excipient.

20

10. A method for the production of a pharmaceutical composition as claimed in claim 9, characterized in converting at least one compound according to claim 1 with at least one pharmaceutically acceptable excipient into a suitable dosage form.

25

11. A microorganism strain: *Cryphonectria parasitica*, DSM 14453.